Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 571 to 580 of 1447 total matches.
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
® Vol. 57 (1483) December 7, 2015
3. H Haahr and T Heise. A review of the pharmacological properties ...
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by the
FDA; insulin detemir (Levemir) and insulin glargine
(Lantus, Toujeo) were approved earlier.
Ferric Citrate (Auryxia) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
The Medical Letter ® Vol. 57 (1483) December 7, 2015
ADVERSE EFFECTS — Diarrhea occurred in 21% of
patients ...
The FDA has approved ferric citrate (Auryxia –
Keryx), an oral phosphate binder, for treatment of
hyperphosphatemia in patients with chronic kidney
disease (CKD) on dialysis. It is the second iron-based
phosphate binder to be approved in the US, and the
first that causes significant systemic absorption of
iron. Auryxia is not FDA-approved for treatment of
iron deficiency anemia.
Deoxycholic Acid (Kybella) for Double Chin
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
-controlled study. J Eur Acad Dermatol
Venereol 2014; 28:1707.
166
The Medical Letter ® Vol. 57 (1483 ...
The FDA has approved the use of subcutaneous
injections of deoxycholic acid (Kybella – Kythera/Allergan) to improve the appearance of moderate
to severe convexity or fullness associated with submental
fat (double chin) in adults. It is the first drug
approved for this indication.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
hours (terminal)
158
The Medical Letter ® Vol. 57 (1482) November 23, 2015
1. Dabigatran etexilate ...
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is the
first specific reversal agent to become available for
one of the new oral anticoagulants.
Bexsero - A Second Serogroup B Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
or anatomic or functional
159
The Medical Letter ® Vol. 57 (1482) November 23, 2015
asplenia ...
The FDA has approved Bexsero (Novartis/GSK), a
vaccine that protects against invasive meningococcal
disease caused by Neisseria meningitidis serogroup
B. It is the second serogroup B meningococcal vaccine
to be approved in the US; Trumenba was the first.
Both vaccines are approved for use in persons 10-25
years old. Bexsero is approved in Europe, Canada, and
Australia for use in children as young as 2 months old.
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
in trial
2). Responses were maintained for 52 weeks.
162
The Medical Letter ® Vol. 57 (1482) November 23 ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...
Cobicistat (Tybost) and Combinations for HIV
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
-blind trial in 692 treatment-naive
160
The Medical Letter ® Vol. 57 (1482) November 23, 2015
HIV ...
Cobicistat, a pharmacokinetic enhancer that boosts
levels of some HIV drugs but has no antiretroviral
activity of its own, is now available alone as Tybost
(Gilead) and in fixed-dose combinations with the
protease inhibitors atazanavir (Evotaz — BMS) and
darunavir (Prezcobix — Janssen) for treatment of
HIV-1 infection. Both atazanavir and darunavir have
traditionally been used in combination with the
CYP3A inhibitor ritonavir (Norvir) to boost their serum
concentrations, but neither is available in a fixed-dose
combination with ritonavir.
A Sumatriptan Patch (Zecuity) for Migraine
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
of 1 vial.
152
The Medical Letter ® Vol. 57 (1481) November 9, 2015
of patients and 1.6% experienced ...
The FDA has approved a sumatriptan iontophoretic
transdermal system (Zecuity – Teva) for acute treatment
of migraine in adults. Sumatriptan, the first
of seven serotonin receptor antagonists (triptans)
approved for this indication, is the most frequently
prescribed migraine treatment in the US. It is also
available in oral, intranasal, and injectable formulations.
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
-policy.
2. Approximate WAC for 45 applications.
155
The Medical Letter ® Vol. 57 (1481) November 9 ...
The FDA has approved a rectal foam formulation of
the corticosteroid budesonide (Uceris - Salix/Valeant)
for induction of remission in patients with active mild
to moderate distal ulcerative colitis (UC) extending
up to 40 cm from the anal verge. Budesonide is also
available as oral extended-release tablets (also
branded as Uceris) for use in patients with UC and as
oral enteric-coated tablets (Entocort EC, and generics)
for treatment of Crohn's disease.
Transdermal Fentanyl (Ionsys) for Postoperative Pain
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
disorders, or bradyarrhythmias should
be monitored for worsening symptoms.
156
The Medical Letter ® Vol ...
A patient-controlled fentanyl iontophoretic transdermal
system (Ionsys – The Medicines Company)
is now available for short-term management of acute
postoperative pain in adults requiring opioid analgesia
in the hospital. Before using Ionsys, patients must
be titrated to a comfortable level of analgesia with
another opioid formulation.